Réponse histologique complète d’un cancer colique métastatique de phénotype MisMatch Repair déficient/MicroSatellite Instable après immunothérapie : à propos d’un cas

Brochard, Camille; Chicaud, Matthieu; Colle, Raphaël; Parc, Yann; Svrcek, Magali

doi:10.1016/j.annpat.2021.12.008

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although surgical resection in combination with chemotherapy is recognized as the optimal treatment for this lethal malignancy, the long-term survival remains unsatisfactory owing to the late detection, early recurrence, and aggressive biological manner of the tumor ( 8 ). In recent years, immunotherapy with immune checkpoint inhibitors (ICIs) has shown beneficial effects and good safety for various solid cancers including non-small cell lung cancer ( 9 ), gallbladder carcinosarcoma ( 10 ), bladder urothelial carcinoma ( 11 ), colorectal adenocarcinoma ( 12 ), etc. For gastric cancer, immunotherapy has also drastically improved the treatment options in the advanced phase, especially for chemorefractory gastric cancer ( 4 , 13 ).…”

Section: Introductionmentioning

confidence: 99%

Pathologic complete response of hepatoid adenocarcinoma of the stomach after chemo-immunotherapy: A rare case report and literature review

et al. 2023

View full text Add to dashboard Cite

BackgroundHepatoid adenocarcinoma of the stomach (HAS) is a highly malignant subtype of gastric carcinoma with specific clinicopathological features and extremely poor prognosis. We present an exceedingly rare case of complete response after chemo-immunotherapy.Case DescriptionA 48-year-old woman with highly elevated serum alpha-fetoprotein (AFP) level was found to have HAS verified by pathological examination based on gastroscopy. Computed tomography scan was done and TNM staging of the tumor was T4aN3aMx. Programmed cell death ligand-1 (PD-L1) immunohistochemistry was performed, revealing a negative PD-L1 expression. Chemo-immunotherapy including oxaliplatin plus S-1 and PD-1 inhibitor terelizumab was given to this patient for 2 months until the serum AFP level decreased from 748.5 to 12.9 ng/mL and the tumor shrank. D2 radical gastrectomy was then performed and histopathology of the resected specimen revealed that the cancerous cells had disappeared. Pathologic complete response (pCR) was achieved and no evidence of recurrence has been found after 1 year of follow-up.ConclusionsWe, for the first time, reported an HAS patient with negative PD-L1 expression who achieved pCR from the combined chemotherapy and immunotherapy. Although no consensus has been reached regarding the therapy, it might provide a potential effective management strategy for HAS patient.

show abstract